Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung Cancer.
Tozuka T, Noro R, Yoshida K, Takahashi S, Hirao M, Matsuda K, Kato Y, Nakamichi S, Takeuchi S, Matsumoto M, Miyanaga A, Kunugi S, Honda K, Adachi J, Seike M. Tozuka T, et al. Among authors: miyanaga a. JTO Clin Res Rep. 2024 Mar 21;5(4):100668. doi: 10.1016/j.jtocrr.2024.100668. eCollection 2024 Apr. JTO Clin Res Rep. 2024. PMID: 38646155 Free PMC article.
The anticancer effect of histone deacetylase inhibitors and combination with the cytotoxic agents in lung cancer cells: biological analyses for future clinical application.
Noro R, Miyanaga A, Shimokawa T, Kuribayashi H, Mizutani H, Minegishi Y, Okano T, Seike M, Soeno C, Kataoka K, Matsuda K, Yoshimura A, Gemma A. Noro R, et al. Among authors: miyanaga a. J Nippon Med Sch. 2009 Feb;76(1):44-6. doi: 10.1272/jnms.76.44. J Nippon Med Sch. 2009. PMID: 19305113 Free article. No abstract available.
Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression.
Noro R, Miyanaga A, Minegishi Y, Okano T, Seike M, Soeno C, Kataoka K, Matsuda K, Yoshimura A, Gemma A. Noro R, et al. Among authors: miyanaga a. Cancer Sci. 2010 Jun;101(6):1424-30. doi: 10.1111/j.1349-7006.2010.01559.x. Epub 2010 Mar 10. Cancer Sci. 2010. PMID: 20384633 Free article.
Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer.
Yoshimura A, Noro R, Miyanaga A, Mizutani H, Kosaihira S, Minegishi Y, Seike M, Hino M, Ando M, Nomura K, Okano T, Kobayashi K, Gemma A; East Japan Chesters Group. Yoshimura A, et al. Among authors: miyanaga a. Anticancer Res. 2012 Oct;32(10):4473-8. Anticancer Res. 2012. PMID: 23060575 Clinical Trial.
Alternating chemotherapy with amrubicin plus cisplatin and weekly administration of irinotecan plus cisplatin for extensive-stage small cell lung cancer.
Noro R, Yoshimura A, Yamamoto K, Miyanaga A, Mizutani H, Minegishi Y, Seike M, Kubota K, Kosaihira S, Hino M, Ando M, Nomura K, Okano T, Kobayashi K, Uematsu K, Gemma A; East Japan Chesters Group. Noro R, et al. Among authors: miyanaga a. Anticancer Res. 2013 Mar;33(3):1117-23. Anticancer Res. 2013. PMID: 23482789 Clinical Trial.
150 results